Pyridostigmine bromide sustained-release tablet and preparation method thereof

A clear, tablet-core technology, applied in the field of medicine, can solve problems such as unseen prescriptions and research reports on preparation processes

Inactive Publication Date: 2011-11-30
CHONGQING MEDICAL UNIVERSITY
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After searching patents and literature, although there are reports mentioning pyridostigmine bromi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyridostigmine bromide sustained-release tablet and preparation method thereof
  • Pyridostigmine bromide sustained-release tablet and preparation method thereof
  • Pyridostigmine bromide sustained-release tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The tablet core is a skeleton tablet, including the following components, and its weight composition or weight percentage is:

[0035] Pyridostigmine bromide 18 parts

[0036] HPMC K15M 12 copies

[0037] Microcrystalline cellulose 3.5 parts

[0038] Lactose 2 parts

[0039] Talcum powder 0.2 parts

[0040] The components contained in the coating solution account for the weight percent of the coating solution as follows:

[0041] Cellulose acetate 3%

[0042] PEG 6000 0.06%

[0043] Talc 0.01%

[0044]The preparation method comprises the following steps: (1) tablet core preparation: weigh pyridostigmine bromide, HPMC, microcrystalline cellulose, lactose and sieve according to tablet core prescription quantity, mix well, use 95% ethanol solution as wetting agent Prepare soft materials, sieve and granulate, dry the wet granules, adjust the granules, add talcum powder and mix evenly, put the above mixture into a tablet machine and compress into tablets to obtain tab...

Embodiment 2

[0046] The tablet core is a skeleton tablet, including the following components, and its weight composition or weight percentage is:

[0047] Pyridostigmine bromide 18 parts

[0048] HPMC K15M 8 parts

[0049] HPMC K15M 8 parts

[0050] 5 parts microcrystalline cellulose

[0051] Lactose 3 parts

[0052] Talcum powder 0.3 parts

[0053] The component that coating liquid contains accounts for the percentage by weight of coating liquid:

[0054] Ethylcellulose 4%

[0055] Polyethylene glycol PEG 0.08%

[0056] Talc 0.02%

[0057] The preparation method is basically the same as in Example 1. Alternatively, the coating is applied with an aqueous dispersion of the coating components.

Embodiment 3

[0059] The tablet core is a skeleton tablet, including the following components, and its weight composition is as follows:

[0060] The tablet core is a skeleton tablet, including the following components, and its weight composition or weight percentage is:

[0061] 9 parts of pyridostigmine bromide

[0062] HPMC K100M 8 parts

[0063] 2 parts microcrystalline cellulose

[0064] 1 part lactose

[0065] Talc powder 0.1 parts

[0066] A coating layer composed of a coating liquid comprising the following components, the weight percentage of the components contained in the coating liquid is:

[0067] Ethylcellulose 2%

[0068] Polyglycol PEG 0.04%

[0069] Talc 0.01%

[0070] The preparation method is basically the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicinal preparations, and discloses a formula of pyridostigmine bromide sustained-release tablets taken twice every day and used for treating myasthenia gravis, postoperative functional intestinal tympanites and uroschesis and a preparation process. The preparation is in a form of sustained-release tablets consisting of skeleton tablet cores and coatings, wherein the skeleton tablet core consists of pyridostigmine bromide, sustained-release agent and the like. The pyridostigmine bromide sustained-release tablets can overcome the defects of current marketed common medicinal tablets, realize sustained release to ensure relatively stable blood concentration and longer acting time, have the advantages of low toxic or side effects and convenience for administration, and can keep effective blood concentration for relatively long time, reduce the administration times, improve the compliance of patients and reduce the side effect caused by over high peak concentration. The preparation process of the pyridostigmine bromide sustained-release tablets is simple, low in cost, easy to control and easy for industrialized production.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a pyridostigmine bromide sustained-release tablet and a preparation method thereof. Background technique [0002] Pyridostigmine bromide is a cholinesterase inhibitor, which can increase the concentration of acetylcholine at the nerve-muscle junction, effectively replace the molecules of non-depolarizing muscle relaxants from the posterior membrane, and make acetylcholine play the role of transmitter. Excitement conduction, thereby restoring muscle tension, is often used clinically to treat myasthenia gravis, postoperative functional flatulence and urinary retention. . After oral administration of 60 mg of the drug, the peak time is 1 to 5 hours, and the half-life is about 3.3 hours. Listed products include sugar-coated tablets with a specification of 60mg, generally 60-120mg (1-2 tablets) for adults, orally once every 3-4 hours. The medicine needs to be taken for a long time during clin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/32A61K9/36A61K31/4425A61K47/38A61P21/04A61P1/14A61P13/00
Inventor 张景勍王睿
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap